Grifols SA

GRFS

Company Profile

  • Business description

    Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

  • Contact

    Avinguda de la Generalitat, 152-158
    Parc de Negocis Can Sant Joan
    Sant Cugat del Valles
    Barcelona08174
    ESP

    T: +34 935710500

    E: [email protected]

    https://www.grifols.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2025

    Employees

    23,822

Stocks News & Analysis

stocks

6 undervalued stocks with low beta

Berkshire Hathaway and Verizon are among the low-volatility stocks that trade at a discount.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,772.001.00-0.01%
CAC 407,637.7428.17-0.37%
DAX 4023,800.13109.48-0.46%
Dow JONES (US)44,094.77275.500.63%
FTSE 1008,735.3025.66-0.29%
HKSE24,072.28211.87-0.87%
NASDAQ20,369.7396.270.47%
Nikkei 22539,986.33501.06-1.24%
NZX 50 Index12,734.53131.711.05%
S&P 5006,204.9531.880.52%
S&P/ASX 2008,541.101.20-0.01%
SSE Composite Index3,444.4320.200.59%

Market Movers